Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 242

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 242
---
 foreign private issuers. Accordingly, Living Homeopathy will be required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, Living Homeopathy is exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and Living Homeopathy’s executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

All information filed with the SEC can be obtained over the internet
at the SEC’s website at www.sec.gov. You can request copies of documents, upon payment of a duplicating fee, by writing to the SEC.

No dealers, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.

<div align='center'>139

LIVING HOMEOPATHY INTERNATIONAL LIMITED AND ITS SUBSIDIARIES

TABLE OF CONTENTS</div>

| Report of Independent Registered Public Accounting Firm (PCAOB ID: 1171)                               
 Consolidated Balance Sheets as of March 31, 2024 and 2023                                              
 Consolidated Statements of Income and Comprehensive Income for the Years Ended March 31, 2024 and 2023 |     | Page 
 F-2  
 F-3  
 F-4  |
|:-------------------------------------------------------------------------------------------------------|:----|:-----|
| Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended March 31, 2024 and 2023 |     | F-5  |
| Consolidated Statements of Cash Flows for the Years Ended March 31, 2024 and 2023                      |     | F-6  |
| Notes to the Consolidated Financial Statements                                                         |     | F-7  |

| Report                                                                                                                            
 of Independent Registered Public Accounting Firm (PCAOB ID: 1171)                                                                 
 Unaudited                                                                                                                         
 Interim Condensed Consolidated Balance Sheet as of September 30, 2024 and Consolidated Balance Sheet as of March 31, 2024         
 Unaudited